Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Mantle Zone

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    87 result(s) found for: Mantle Zone. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2007-001108-19 Sponsor Protocol Number: SAKK 36/06 Start Date*: 2008-09-23
    Sponsor Name:SAKK
    Full Title: Master protocol for mantle cell lymphoma. A multicenter phase II trial testing Everolimus ( RAD001) for the treatment of patients with relapsed or thérapy resistant mantle cell lymphoma. Protocol S...
    Medical condition: Traitement des lymphomes du manteau en deuxième ou troisième ligne (1ère ou 2nd rechute)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061275 Mantle cell lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-012807-25 Sponsor Protocol Number: IIL-MCL0208 Start Date*: 2010-01-28
    Sponsor Name:IIL INTERGRUPPO ITALIANO LINFOMI ONLUS
    Full Title: A PHASE III MULTICENTER, RANDOMIZED STUDY WITH LENALIDOMIDE (Revlimid) MAINTENANCE VERSUS OBSERVATION AFTER INTENSIFIED INDUCTION REGIMEN CONTAINING RITUXIMAB FOLLOWED BY HIGH DOSE CHEMOTHERAPY A...
    Medical condition: Mantel cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061275 LLT
    9.1 10061275 LLT
    9.1 10061275 LLT
    9.1 10061275 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing) PT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-011433-27 Sponsor Protocol Number: ML22489 Start Date*: 2009-11-04
    Sponsor Name:Roche Romania SRL
    Full Title: A phase II multicenter open-label study of MabThera (Rituximab) addition to regularly prescribed chemotherapy in patients with untreated Mantle Cell Lymphoma
    Medical condition: Mantle Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061275 Mantle cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000548-33 Sponsor Protocol Number: LyMa101 Start Date*: 2016-07-20
    Sponsor Name:LYSARC
    Full Title: Phase II study to evaluate the efficacy of upfront obinutuzumab in mantle cell lymphoma patients treated by DHAP followed by autologous transplantation plus obinutuzumab maintenance then MRD driven...
    Medical condition: Mantle Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061275 Mantle cell lymphoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004628-31 Sponsor Protocol Number: FIL_V-RBAC Start Date*: 2018-05-15
    Sponsor Name:Fondazione Italiana Linfomi ONLUS
    Full Title: Rituximab, bendamustine and cytarabine followed by venetoclax (V-RBAC) in high-risk elderly patients with mantle cell lymphoma (MCL)
    Medical condition: Mantle Cell Lymphoma in elderly patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10026799 Mantle cell lymphoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002117-28 Sponsor Protocol Number: ACE-LY-004 Start Date*: 2015-05-06
    Sponsor Name:Acerta Pharma B.V.
    Full Title: An Open-label, Phase 2 Study of ACP-196 in Subjects with Mantle Cell Lymphoma
    Medical condition: Mantle Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10026798 Mantle cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) BE (Ongoing) CZ (Completed) ES (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-001500-39 Sponsor Protocol Number: LM01 Start Date*: 2005-09-06
    Sponsor Name:G.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI
    Full Title: A phase II GISL study of R-HyperCVAD in the treatment of patients with Mantle cell Lymphoma
    Medical condition: treatment of patients with Mantle cell Lymphoma with tha combination R-HyperCVAD
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061275 Mantle cell lymphoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003893-17 Sponsor Protocol Number: SAKK36/13 Start Date*: 2017-11-23
    Sponsor Name:SAKK, Swiss Group for Clinical Cancer Research
    Full Title: Combination of ibrutinib and bortezomib followed by ibrutinib maintenance to treat patients with relapsed and refractory mantle cell lymphoma; a multicenter Phase I/II trial
    Medical condition: Histologically confirmed mantle cell lymphoma in need of systemic treatment Refractory or relapsed disease after pretreatment of non-bortezomib containing chemotherapy including high-dose therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026801 Mantle cell lymphoma refractory PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026800 Mantle cell lymphoma recurrent PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-015909-39 Sponsor Protocol Number: INT5909 Start Date*: 2009-12-02
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Phase I/II trial of dexamethasone, ofatumumab and bendamustine [Treanda] (DOT) as first-line treatment of mantle-cell lymphoma (MCL) in the elderly
    Medical condition: Mantle-cell lymphoma (MCL)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061275 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004158-17 Sponsor Protocol Number: GELTAMO-IMCL-2015 Start Date*: 2016-02-15
    Sponsor Name:GELTAMO (Grupo Cooperativo Español de Llinfoma/Trasplante Autólogo de Médula Ósea)
    Full Title: Multicentric phase II trial to evaluate the efficacy and safety of Ibrutinib in combination with rituximab in patients with indolent clinical forms of Mantle Cell Lymphoma.
    Medical condition: Mantle Cell Lyphoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004851 10026798 Mantle cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005439-41 Sponsor Protocol Number: PLRG-10/ML29157 Start Date*: 2017-08-13
    Sponsor Name:Polish Lymphoma Research Group (PLRG)
    Full Title: EVALUATION OF EFFICACY AND SAFETY OF OBINUTUZUMAB PREEMPTIVE TREATMENT AT THE TIME OF THE MOLECULAR RELAPSE AFTER FIRST LINE IMMUNOCHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION IN MANTLE C...
    Medical condition: Molecular relapse after the first line immunochemotherapy with autologous stem cell transplantation in mantle cell lymphoma (MCL) patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061275 Mantle cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-005541-36 Sponsor Protocol Number: NLG-MCL6 Start Date*: 2014-11-27
    Sponsor Name:Nordic Lymphoma Group
    Full Title: A phase II trial of ibrutinib, lenalidomide and rituximab for patients with relapsed/refractory mantle cell lymphoma.
    Medical condition: Relapsed/refractory mantle cell lymphoma,
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10026799 Mantle cell lymphoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-004910-37 Sponsor Protocol Number: OASIS-II Start Date*: 2021-05-11
    Sponsor Name:LYSARC
    Full Title: A randomized phase II trial evaluating Ibrutinib plus CD20 Ab and Ibrutinib-Venetoclax plus CD20 Ab in patients with untreated mantle cell lymphoma
    Medical condition: Untreated mantle cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061275 Mantle cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001557-85 Sponsor Protocol Number: 5.0 Start Date*: 2011-08-22
    Sponsor Name:Nordic Lymphoma Group
    Full Title: NLG-MCL5 (MARiT) Rituximab, High Dose Ara-C and Dexamethasone Followed by BEAM in Mantle Cell Lymphoma Patients <66 years A Nordic Lymphoma Group and British Lymphoma Group Phase-II Trial
    Medical condition: Mantle cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026799 Mantle cell lymphoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing) DK (Prematurely Ended) FI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-004039-30 Sponsor Protocol Number: MCL5(MARiT) Start Date*: 2012-04-03
    Sponsor Name:PLymouth Hospitals NHS Trust
    Full Title: Rituximab, High Dose Ara-C and Dexamethasone Followed by BEAM in Mantle Cell Lymphoma Patients <66 Years
    Medical condition: Mantle Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026799 Mantle cell lymphoma NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000711-88 Sponsor Protocol Number: PCI-32765MCL2001 Start Date*: 2012-09-13
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2, Multicenter, Single-Arm, Study to Evaluate the Efficacy and Safety of Single-Agent Bruton' s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects with Mantle Cell Lymphoma Who Progres...
    Medical condition: Mantle Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061275 Mantle cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) GB (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-001430-16 Sponsor Protocol Number: 3066K1-305-WW Start Date*: 2005-04-20
    Sponsor Name:Wyeth Research, Division of Wyeth Pharmaceuticals, Inc. Clinical Research and Development
    Full Title: An Open-label, Randomized, Phase 3 Trial of intravenous Temsirolimus (CCI-779) at two Dose Levels Compared to Investigator's Choice Therapy in relapsed, Refractory Subjects with Mantle Cell lymphom...
    Medical condition: Mantle Cell Lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) SE (Completed) GB (Completed) DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-000540-25 Sponsor Protocol Number: FIL_KLIMT Start Date*: 2019-06-25
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: Carfilzomib (K) plus Lenalidomide (R) and Dexamethasone (D) for BTK inhibitors relapsed-refractory or intolerant mantle cell lymphomas: a phase II study
    Medical condition: BTK inhibitors relapsed-refractory or intolerant mantle cell lymphomas
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061275 Mantle cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002935-30 Sponsor Protocol Number: 20-01434 Start Date*: 2023-01-20
    Sponsor Name:University Medical Center of the Johannes Gutenberg-University Mainz
    Full Title: Venetoclax in combination with the BTK inhibitor Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients with treatment naive Mantle Cell Lymphom...
    Medical condition: Mantle Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10026799 Mantle cell lymphoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004093-27 Sponsor Protocol Number: ML20493 Start Date*: 2007-04-04
    Sponsor Name:Roche (Hungary) Ltd.
    Full Title: A multicenter, phase II, open-label study evaluating the benefit of addition of MabThera (rituximab) to standard chemotherapies in patients with previously untreated mantle cell lymphoma.
    Medical condition: Mantle cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061275 Mantle cell lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 20:57:06 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA